Bausch + Lomb (BLCO) Could Be 57% Undervalued As Board Refresh Draws Attention
Bausch + Lomb (BLCO) drew fresh attention after appointing four new directors on August 5, 2026, replacing four outgoing board members. Investors are now weighing how this refreshed oversight might influence the company.
See our latest analysis for Bausch + Lomb.
Bausch + Lomb’s share price has shown building momentum, with a 7 day share price return of 3.85% and a 30 day share price return of 6.39%. The 1 year total shareholder return sits at 20.60%, compared with a 3 year total shareholder return decline of 10.68%.
If the board refresh has you thinking about future opportunities in healthcare, it can be useful to see what else is on the move through our 44 healthcare AI stocks
Bausch + Lomb shares have already reacted to the board shake up and recent gains. The next step is to determine whether the current valuation still leaves enough upside for new buyers or instead tilts the risk reward toward caution.
Most Popular Narrative: 56.7% Undervalued
Compared with Bausch + Lomb’s last close at $16.98, the most followed narrative assigns a fair value of $39.23 per share, which implies a large valuation gap that investors are watching closely.
For more than a week following the company’s Annual General Meeting (AGM), shareholders have been left without a single published result, filing, press release, or confirmation of what occurred inside the meeting. This absence of disclosure is not normal, not industry standard, and not aligned with the obligations of a publicly traded company.
The narrative behind Bausch + Lomb’s fair value emphasizes a path to profitability, firm revenue growth assumptions, and healthier margins. Want to see how these pieces are connected and which cash flow profile underpins that $39.23 figure?
Result: Fair Value of $39.23 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Bausch + Lomb narrative could be challenged if governance concerns around AGM disclosure persist or if the company’s recent net income loss of US$171 million continues.
Find out about the key risks to this Bausch + Lomb narrative.
Next Steps
If this mix of optimism and concern around Bausch + Lomb leaves you undecided, review the numbers now and form your own view with the 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond Bausch + Lomb?
If Bausch + Lomb has sharpened your focus on opportunities, do not stop here. Broaden your watchlist now so you are not the one catching up later.
- Target resilient income by reviewing companies identified as 11 dividend fortresses that could help anchor your portfolio with consistent cash returns.
- Spot potential bargains early by scanning the screener containing 19 high quality undiscovered gems before they attract wider attention and tighter pricing.
- Strengthen your downside protection by concentrating on 90 resilient stocks with low risk scores that aim to balance growth potential with measured volatility.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com